CRISPR Trials on Hold: Intellia Therapeutics Faces FDA Scrutiny Amid Safety Concerns
November 1, 2025
The world of gene editing has revolutionized medical science, offering potential cures
- April 24, 2026
FDA, EMA, and regulatory affairs
The world of gene editing has revolutionized medical science, offering potential cures
The U.S. Food and Drug Administration (FDA) is taking significant steps to
In the complex landscape of the biopharma industry, drug pricing remains a
CRINETICS REPORT Overview Leadership Mission Products Financials Strengths Challenges News Crinetics Pharmaceuticals,
In the ever-evolving biopharmaceutical landscape, Eli Lilly has taken center stage with
In a groundbreaking development for the biopharma industry, Sonoma Biotherapeutics has unveiled
The landscape of biopharmaceuticals is evolving, paving the way for critical advancements
BioMarin Pharmaceutical has recently announced a significant development regarding its gene therapy,
In a surprising turn of events, Kevin Ali, the CEO of Organon,
In an alarming turn of events, recent findings from the U.S. Food
In a significant move to enhance the efficiency of drug approval processes,
Arcturus Therapeutics, a biotechnology company specializing in RNA medicines, recently encountered significant
Alkermes, a prominent name in the biopharmaceutical sector, recently made headlines with
In a significant leap forward for cancer detection technology, Grail, a pioneering
Galapagos NV shuts down its cell therapy division, cuts 365 jobs, and
In a groundbreaking move for the biopharma sector, Iambic Therapeutics has announced
In recent weeks, Alto Neuroscience has witnessed a remarkable surge in its
The Congressional Budget Office (CBO) made headlines with its recent announcement about
The biopharmaceutical landscape is on the cusp of a technological revolution, with
The biopharma landscape is constantly evolving, with a growing focus on innovative
